Macular Degeneration Trial, Recruiting NCT07500324 Sponsor: Fondazione G.B. Bietti, IRCCS Condition: Macular Degeneration
Back to Macular Degeneration

Macular Degeneration Trial, Recruiting

NCT07500324
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older
  • People who are able to understand what the study involves and are willing to sign a written agreement to participate
  • People who are willing and able to attend study visits and follow study procedures

For people joining as "case" participants (those with eye conditions being studied):

  • People who have age-related macular degeneration at an intermediate or advanced stage, including a form called geographic atrophy or the wet (neovascular) form
  • People who have diabetic retinopathy (damage to the eye caused by diabetes), whether mild or more advanced, with or without related swelling in the central part of the eye
  • People who are having surgery for a retinal detachment (where the light-sensitive layer at the back of the eye lifts away), either for the first time or for a repeat occurrence

For people joining as "control" participants (those without the eye conditions being studied):

  • People scheduled for cataract surgery who have no known retinal diseases
  • Outpatients (people seen in a clinic, not admitted to hospital) who have no known retinal diseases
  • For the retinal detachment comparison group: people having surgery on the central part of the back of the eye (such as for a wrinkled or holes in the central retina) or cataract surgery where the retina is still attached

Who may not be able to join:

  • People under 18 years of age
  • People who currently have an infectious disease affecting the eye
  • People who have certain abnormalities in specific proteins found in the blood (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +390684009442

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Fondazione G.B. Bietti, IRCCS
Registry
ClinicalTrials.gov
Start date
24 January 2024
Est. completion
1 January 2027

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Identification and Validation of Proteomic Biomarkers

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov